Colleen Tupper Sells 10,445 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Stock

Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) CFO Colleen Tupper sold 10,445 shares of the company's stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $30.01, for a total value of $313,454.45. Following the sale, the chief financial officer now directly owns 165,246 shares in the company, valued at approximately $4,959,032.46. This represents a 5.95 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Colleen Tupper also recently made the following trade(s):

• On Thursday, March 6th, Colleen Tupper sold 1,949 shares of Collegium Pharmaceutical stock. The stock was sold at an average price of $30.00, for a total transaction of $58,470.00.

Collegium Pharmaceutical Trading Up 0.7 %

Shares of NASDAQ:COLL traded up $0.21 during midday trading on Monday, reaching $29.67. The company had a trading volume of 288,097 shares, compared to its average volume of 415,691. The company has a fifty day simple moving average of $30.85 and a two-hundred day simple moving average of $32.93. The firm has a market cap of $934.19 million, a price-to-earnings ratio of 12.79 and a beta of 0.99. Collegium Pharmaceutical, Inc. has a 1-year low of $27.28 and a 1-year high of $42.29. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last announced its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, topping the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The company had revenue of $181.95 million during the quarter, compared to analysts' expectations of $179.68 million. Research analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Remove Ads

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. increased its holdings in shares of Collegium Pharmaceutical by 173.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company's stock valued at $10,711,000 after purchasing an additional 175,892 shares during the period. Penserra Capital Management LLC purchased a new position in Collegium Pharmaceutical during the third quarter valued at approximately $757,000. Barclays PLC increased its stake in Collegium Pharmaceutical by 152.2% in the 3rd quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company's stock valued at $2,899,000 after buying an additional 45,291 shares during the period. Sanctuary Advisors LLC lifted its position in Collegium Pharmaceutical by 10.7% in the 3rd quarter. Sanctuary Advisors LLC now owns 17,976 shares of the specialty pharmaceutical company's stock worth $695,000 after buying an additional 1,731 shares in the last quarter. Finally, FMR LLC boosted its stake in shares of Collegium Pharmaceutical by 1,532.2% during the 3rd quarter. FMR LLC now owns 37,752 shares of the specialty pharmaceutical company's stock valued at $1,459,000 after buying an additional 35,439 shares during the period.

Analysts Set New Price Targets

Several brokerages have weighed in on COLL. Piper Sandler cut their target price on Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating on the stock in a research note on Tuesday, February 4th. Needham & Company LLC raised Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 price objective on the stock in a research note on Friday, January 10th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $50.00 target price on shares of Collegium Pharmaceutical in a report on Friday, January 10th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $43.60.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.